In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maine Fires the First Price Control Salvo

Executive Summary

Although there's been plenty of noise coming out capitol Hill regarding the issues of prescription drug prices and expanding Medicare to cover such drugs, sharp debate on the merits of over a dozen pieces of proposed legislation--as well as election year politics--have stalled congressional action. But the states are beginning to make their own moves on the price control front, with Maine enacting the first price control (well, almost) legislation. However the new Maine law, as well as any similar laws passed by other states will likely face tough legal challenges.

You may also be interested in...



US FDA Critic Leads House Appropriators, Consumer Health Ally Heads Energy And Commerce

Rosa DeLauro prevails over fellow Democrats Debbie Wasserman Schultz and Marcy Kaptur for Appropriations chair. Frank Pallone gets unanimous support from Democrats to continue as Energy and Commerce chair.

CMS Final Medicare Outpatient Rule Gives Patients More Surgical Site Choices, At Lower Costs

The US Medicare agency is offering more lower-cost alternative sites for 2021 surgical procedures to be covered under its OPPS and ASC final rule.

Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV

Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.

Topics

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel